Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
The incidence and severity of gastrointestinal side effects may increase with higher doses or more rapid dose escalation, as commonly employed for greater weight reduction
Orforglipron is projected to generate about $1.6 billion in revenue in 2026, compared with $11.4 billion for Wegovy, which itself is seen easing from roughly $12.4 billion in 2025 as competition intensifies
By helping patients tune into their hunger and fullness cues, we aim to support healthy, sustainable eating patterns
Side effect documentation with severity ratings and duration
US$ 20.63
US$ 27.24
US$ 28.99
US$ 25.76
